Idorsia Pharmaceuticals Ltd.   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Allschwil Switzerland (2017)

Organization Overview

First Clinical Trial
2017
NCT03245229
First Marketed Drug
2022
daridorexant (Quviviq)
First NDA Approval
2022
daridorexant (Quviviq)
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

IDORSIA | Idorsia Pharmaceuticals | Idorsia Pharmaceuticals Ltd. | IDORSIA PHARMACEUTICALS LTD. | Idosia Pharmaceuticals Ltd